Supporting women's cardiovascular health.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 946 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
H. RES. 946

               Supporting women's cardiovascular health.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 25, 2022

Mrs. Trahan (for herself, Mr. Welch, Mr. Trone, Ms. Sewell, Mr. Carter 
of Georgia, Mr. Fitzpatrick, Mr. Bacon, Mr. Moulton, Mr. Rush, and Ms. 
Lois Frankel of Florida) submitted the following resolution; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                               RESOLUTION


 
               Supporting women's cardiovascular health.

Whereas cardiovascular disease is the leading cause of death for women in the 
        United States;
Whereas women with cardiovascular disease are often underdiagnosed or 
        misdiagnosed;
Whereas women are underrepresented in clinical trials which assess unique 
        benefits and risks of new cardiovascular treatments;
Whereas women of color are particularly underrepresented in clinical trials of 
        new cardiovascular treatments;
Whereas addressing known barriers to clinical trial participation will increase 
        the number of women participating in clinical trials;
Whereas there is a critical need for increased participation in cardiovascular 
        intervention clinical trials by women; and
Whereas there exists a lack of awareness about treatment options for women, 
        including technologies to enable heart recovery or heart muscle 
        recovery, which enables a superior quality of life following a heart 
        event: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) supports efforts to increase participation of women in 
        cardiovascular intervention clinical trials;
            (2) recognizes the critical importance of education and 
        awareness of advanced cardiovascular treatment options for 
        women; and
            (3) encourages health care providers, drug and device 
        manufacturers, and patient advocates to collaborate on ways to 
        improve cardiovascular health among women.
                                 <all>